Literature DB >> 11779872

Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells.

Junko Sonoyama1, Itaru Matsumura, Sachiko Ezoe, Yusuke Satoh, Xian Zhang, Yoshihisa Kataoka, Emi Takai, Masao Mizuki, Takashi Machii, Hiroshi Wakao, Yuzuru Kanakura.   

Abstract

BCR/ABL tyrosine kinase generated from the chromosomal translocation t(9;22) causes chronic myelogenous leukemia and acute lymphoblastic leukemia. To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. The inducibly expressed DN Ras (N17), STAT5 (694F), and DN phosphatidylinositol 3-kinase (Delta p85) inhibited the growth by 90, 55, and 40%, respectively. During the growth inhibition, the expression of cyclin D2 and cyclin D3 was suppressed by N17, 694F, or Delta p85; that of cyclin E by N17; and that of cyclin A by Delta p85. In addition, N17 induced apoptosis in a small proportion of K562, whereas 694F and Delta p85 were hardly effective. In contrast, coexpression of two DN mutants in any combinations induced severe apoptosis. During these cultures, the expression of Bcl-2 was suppressed by N17, 694F, or Delta p85, and that of Bcl-XL by N17. Furthermore, although K562 was resistant to interferon-alpha- and dexamethasone-induced apoptosis, disruption of one pathway by N17, 694F, or Delta p85 sensitized K562 to these reagents. These results suggested that cooperation among these molecules is required for full leukemogenic activities of BCR/ABL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779872     DOI: 10.1074/jbc.M111501200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation.

Authors:  Jutong Si; Steven J Collins
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

2.  Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.

Authors:  Chiara Corrado; Anna Maria Flugy; Simona Taverna; Stefania Raimondo; Giuliana Guggino; Rashida Karmali; Giacomo De Leo; Riccardo Alessandro
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

3.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Authors:  Agata Klejman; Steven J Schreiner; Malgorzata Nieborowska-Skorska; Artur Slupianek; Matthew Wilson; Thomas E Smithgall; Tomasz Skorski
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

4.  Abnormal hematopoiesis in Gab2 mutant mice.

Authors:  Yi Zhang; Ernesto Diaz-Flores; Geqiang Li; Zhengqi Wang; Zizhen Kang; Eleonora Haviernikova; Sara Rowe; Cheng-Kui Qu; William Tse; Kevin M Shannon; Kevin D Bunting
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

5.  Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients.

Authors:  Guangshan Tan; Lei Shi; Qiang Li; Mingjun Wang
Journal:  Cell Prolif       Date:  2015-08       Impact factor: 6.831

6.  From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

Authors:  Michael G Kharas; George Q Daley
Journal:  Genes Cancer       Date:  2010-12

7.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

Review 8.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

9.  ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Authors:  Clara I Aceves-Luquero; Anupriya Agarwal; Juan L Callejas-Valera; Laura Arias-González; Azucena Esparís-Ogando; Luis del Peso Ovalle; Itxaso Bellón-Echeverria; Miguel A de la Cruz-Morcillo; Eva M Galán Moya; Inmaculada Moreno Gimeno; Juan C Gómez; Michael W Deininger; Atanasio Pandiella; Ricardo Sánchez Prieto
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

10.  MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.

Authors:  Jennifer Asmussen; Elisabeth A Lasater; Cheryl Tajon; Juan Oses-Prieto; Young-Wook Jun; Barry S Taylor; Alma Burlingame; Charles S Craik; Neil P Shah
Journal:  Cancer Discov       Date:  2013-12-20       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.